| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 80 | 890 | 450 | 0 | 60 |
| Sales Growth | -91.01% | +97.78% | unch | -100.00% | -14.29% |
| Net Income | -19,380 | -10,640 | -15,120 | -9,690 | -17,260 |
| Net Income Growth | -82.14% | +29.63% | -56.04% | +43.86% | -3.73% |
Timber Pharmaceuticals Inc (TMBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Timber Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company is initially engaged on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. Timber Pharmaceuticals Inc., formerly known as BioPharmX Corporation, is based in NJ, United States.